Details of the Drug

General Information of Drug (ID: DMEFRTZ)

• Drug Name: Lurbinectedin
• Synonyms: UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[1]
leukaemia	2A60-2B33	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Endometrial cancer	2C76	Phase 2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 784.9
  Logarithm of the Partition Coefficient (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 14
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 551 mcgh/L [4]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 107 mcg/L [4]
  Clearance: The total plasma clearance of drug is 11 L/h [4]
  Elimination: Approximately 89% of a given dose is recovered in the feces (<0.2% unchanged) and 6% in the urine (1% unchanged) [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 51 hours [4]
  Metabolism: The drug is metabolized via the CYP3A4 [4]
  Vd: The volume of distribution (Vd) of drug is 504 L [4]
• Chemical Identifiers:
  Formula: C41H44N4O10S
  IUPAC Name: [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
  Canonical SMILES: CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
  InChI: InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
  InChIKey: YDDMIZRDDREKEP-HWTBNCOESA-N
• Cross-matching ID:
  PubChem CID: 57327016
  CAS Number: 497871-47-3
  DrugBank ID: DB12674
  TTD ID: D0V6OA
  ACDINA ID: D01230
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Inhibitor	[1]
Human Deoxyribonucleic acid minor groove (hDNA min)	TTOVXHF	NOUNIPROTAC	Inhibitor	[1]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lurbinectedin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Lurbinectedin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[5]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Lurbinectedin caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[6]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Lurbinectedin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[6]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Lurbinectedin caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[6]
Eslicarbazepine	DMZREFQ	Major	Decreased metabolism of Lurbinectedin caused by Eslicarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[6]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Lurbinectedin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[6]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Lurbinectedin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[7]
Tildrakizumab	DMLW9HG	Moderate	Additive myelosuppressive effects by the combination of Lurbinectedin and Tildrakizumab.	Psoriasis [EA90]	[8]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Lurbinectedin and Risankizumab.	Psoriasis [EA90]	[8]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Lurbinectedin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[6]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Lurbinectedin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[6]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Lactic acid	E00020	612	Acidulant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lurbinectedin 4 mg Injection	4 mg	Injection	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection
• [5] Cerner Multum, Inc. "Australian Product Information.".
• [6] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [7] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [8] Cerner Multum, Inc. "UK Summary of Product Characteristics.".